PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1935276
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1935276
Sinus Dilation Devices Market is estimated to be valued at USD 4.56 Bn in 2026 and is expected to reach USD 7.89 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 4.56 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 11.20% | 2033 Value Projection: | USD 7.89 Bn |
Sinusitis is an inflammation of sinus, which causes nose blockage and avoids mucus drainage. Sinus dilation devices are used in patients with nose drainage issues related to nasal sinusitis or sinuses to expand the sinus openings. Different types of sinus dilation devices can be utilized for patients according to the need of the treatment, which includes balloon sinuplasty systems, rhinoscopes, sinus stents, and functional endoscopic sinus surgery (FESS), and instruments set for sinuses or sinusitis. During balloon sinus dilation procedure, doctor reshapes the patient's sinus pathway with inflated balloons to open the blocked sinus or nasal pathway. Sinus dilation procedures are generally preferred over antibiotics, decongestants, or steroids, as it provides long-lasting and immediate results.
Factors driving the sinus dilation devices market are increasing prevalence of chronic sinusitis, growing preference for minimally invasive surgeries, and favorable reimbursement scenario of surgical treatments for hospital outpatient department. According to the Centers for Disease Control and Prevention (CDC), in 2016, around 26.7 million adults in the U.S. were diagnosed with chronic sinusitis. According to National Center for Biotechnology Information (NCBI), over 600,000 ambulatory sinonasal cases are performed each year in the U.S. Centers for Medicare Services (CMS) reassigned the nasal/sinus endoscopy codes, for instance, sphenoid balloon dilation (31297) and maxillary FESS procedures (31267) were reassigned to higher paying Ambulatory Payment Classifications (APCs). This resulted in a significant payment increase of 52.6%, which increased reimbursed cost of both the endoscopic sinus surgeries from US$ 2,009 in 2015 to US$ 3,066 in 2016.
Furthermore, increasing number of product launches and FDA approvals are expected to drive the market growth.
Key features of the study